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Abstract: 
Thoracic epidural analgesia (TEA) enhances recovery after bowel surgery. Early postoperative 
prolonged-release oral formulation of oxycodone or oxycodone/naloxone is potentially useful as 
a second analgesic step to reduce the duration of TEA. We hypothesized that oxycodone would 
decrease the duration of TEA and combined with naloxone preserve gastrointestinal function. 
Ninety patients undergoing open cystectomy and urinary diversion were enrolled in this 
randomized double-blind, three-arm, parallel-group, placebo-controlled single-center trial 
between September 2015 and February 2017. Exclusion criteria were known allergy to 
oxycodone/naloxone, pulmonary diseases, hepatopathy, analgesics non-naïve patients. From 
postoperative day 3, patients received batches with oxycodone, oxycodone/naloxone or placebo 
every 12h (n=30 in each arm). Reduction of the epidural drug infusion rate was attempted with 
the goal to maintain a pain intensity <3 at rest and <5 (numeric rating score) at mobilization 
during 6h. Primary endpoint was duration of TEA and secondary endpoint return of 
gastrointestinal function. The median duration of TEA did not differ between patients treated 
with oxycodone/naloxone (6.7 [range 3.1-10.3] days), oxycodone (7.0 [3.0-9.1]) or placebo (6.4 
[3.1-8.4]); P=0.88. Time to first defecation was prolonged in the oxycodone group compared to 
the placebo group (difference 22.48 hours ±8.95; P=0.037). In the oxycodone group, we found 
8/30 patients with ileus (27%) compared to 2/28 (7%) in the oxycodone/naloxone group and to 
2/30 (7%) in the placebo group; (P=0.031). Oxycodone, with or without naloxone, did not reduce 
the duration of TEA. Oxycodone alone led to a delayed return of bowel function, whereas the 
combination was not different from placebo.  
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Introduction 
 
Cystectomy combined with urinary diversion is a major abdominal surgery, which is associated 
with a high incidence of postoperative complications (approximately 60%).[34] Gastrointestinal 
complications are frequent (12-25%)[34] and perioperative techniques aiming at an early return 
of bowel function are to be pursued. 
Optimal postoperative pain management is one of the key factors promoting enhanced recovery 
after surgery (ERAS). The perioperative use of thoracic epidural analgesia (TEA) for major 
abdominal surgery is established, not only because of its excellent analgesic properties,[5] but 
also because TEA reduces the postoperative stress response, accelerates the return of bowel 
function,[20; 42] and may lower postoperative morbidity and mortality.[1; 16; 21; 30] Once 
successfully established, TEA is not without limitations and requires constant attention often 
from an acute pain service to achieve and maintain optimal analgesia. Attention must also be 
directed to limiting or avoiding side-effects such as hypotension, orthostatic disturbances or 
motor block, which will reduce the benefits of the technique by preventing the patient from being 
effectively mobilized after surgery.[18; 39] In addition, each supplemental day with an 
indwelling TEA catheter increases the risk of infection,[19] which is associated with a high 
morbidity. Therefore, it is important to develop strategies that reduce the duration of TEA 
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without impairing the benefits. ERAS protocols recommend removing the TEA catheter 48 to 72 
hours after surgery, which should not impair the return of the gastrointestinal function.[3] While 
this approach is well established for colorectal surgery, there is less evidence for small bowel 
surgery or cystectomy with urinary diversion. In addition, the perioperative administration of 
non-steroid anti-inflammatory drugs, as usually recommended in the frame of ERAS programs, is 
of limited use in cystectomy patient as around 75% of these patients have impaired renal 
function. 
In theory, systemic analgesics like oxycodone or combined drug mixtures like 
oxycodone/naloxone could be a valuable option as a second analgesic step, allowing earlier 
removal of the epidural catheter without impairing return of the bowel function.[12; 14; 23] The 
rationale for the combination of oxycodone with naloxone is reduced opioid-induced bowel 
dysfunction, compared with oxycodone alone.[13; 23] However, evidence is scarce concerning 
the benefit of early oral administration of opioids after major abdominal surgery involving small 
bowel resection and anastomosis before return of bowel function.  
The objectives of this study in patients undergoing cystectomy and urinary diversion were: 1) to 
evaluate the effect of oral oxycodone (with and without naloxone), compared to placebo, on 
duration of TEA (primary endpoint), changes in epidural mixture rate, total amount of epidurally-
administered drugs, and amount of systemic administered rescue analgesics; 2) to evaluate the 
effect of the addition of naloxone to oxycodone on the return of gastrointestinal function (first 
flatus, first defecation, incidence of constipation and postoperative ileus, postoperative nausea 
and vomiting). We expected: 1) equal analgesia with a reduced duration of TEA with oxycodone 
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(w or w/h naloxone), compared to placebo; 2) faster return of bowel function with the 
combination of oxycodone with naloxone, compared to oxycodone alone.  
 
Methods: 
Ethics: 
The study was approved by the Ethics Committee of the Canton Bern, Switzerland (Kantonale 
Ethikkommission Bern, Prof Seiler, KEKBE 068/2015), and by the Swiss Agency for 
Therapeutic Products (2015DR4112). It was prospectively registered at ClinicalTrials.gov 
(NCT02516059; principal investigator: P.Y. Wuethrich, M.D.; date of registration: August 3, 
2015) and conducted in compliance with the Declaration of Helsinki and Good Clinical Practice. 
All patients gave written informed consent before participating in the trial. 
Study design, inclusion and exclusion criteria:  
This was an investigator-initiated, prospective, randomized, double-blinded, double-dummy, 
three-arm, parallel-group, placebo-controlled, interventional superiority trial conducted at the 
Department of Urology University Hospital Bern, Switzerland between September 14, 2015 and 
February 28, 2017. Reporting complied with the recommendations of the Consolidated Standards 
of Reporting Trials (CONSORT) statements. 
Consecutive patients presenting for open cystectomy and urinary diversion (ileal conduit, 
orthotopic bladder substitute, continent catheterizable ileal reservoir) were screened for 
eligibility. Participants fulfilling all the following inclusion criteria were eligible for the study: 
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renal function with an estimated glomerular filtration rate > 40 mL*min-1, normal liver function 
and use of TEA. Exclusion criteria were contra-indications to the class of drugs under study (i.e. 
known allergy to oxycodone and/or naloxone or other excipients), women who were pregnant or 
breast feeding (exclusion for surgery per se), known or suspected non-compliance, drug or 
alcohol abuse, inability to follow the procedures of the study (e.g. due to language problems, 
dementia and severe psychiatric disorder), severe bronchial asthma, severe chronic obstructive 
pulmonary disease, severe respiratory depression with hypoxia and/or hypercapnia, moderate to 
severe hepatic impairment, preoperative use of monoaminooxydase-inhibitors, chronic pain 
disease, regular use of antiemetics, laxatives, opioids or other types of analgesics, preoperative 
regular use of non-steroidal anti-inflammatory drugs and steroids. 
Blinding and randomization: 
Batches and blinding were organized by Mundipharma Medical Company (Basel, Switzerland) 
and provided by Mundipharma Research GmbH & Co (Cambridge, UK), granting good 
manufacturing practice. As oxycodone/naloxone tablets were oblong in shape and the oxycodone 
tablets were round, a double dummy approach was inevitable to warrant the full blinding and the 
inability to optically recognize the type of drugs administered. One contained only placebo 
(round and oblong tablets), the second oxycodone (Oxycontin®, Mundipharma Research GmbH 
& Co Cambridge, UK) plus placebo (oblong tablet) and the third a mixture of oxycodone and 
naloxone (Targin®; Mundipharma Research GmbH & Co Cambridge, UK) plus placebo (round 
tablet). The pack for each participant contained enough medication for 5 days: The 
oxycodone/naloxone arm received 2 tablets of 10 mg / 5 mg (active and placebo) for the first day 
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followed by 8 tablets of 20 mg / 10 mg for the remaining 4 days. The oxycodone arm received 2 
tablets of 10 mg (active and placebo) for the first day followed by 8 tablets of 20 mg for the 
remaining 4 days. The placebo arm received 2 tablets (one round placebo tablet and one oblong 
placebo tablet) for the next 5 days. The pack always contained 2 blisters, for example, one 
containing active oxycodone/naloxone medication and the other containing placebo tablets to 
blind the supplies. 
Study nurses from the Department of Urology delivered the randomized blinded drugs to the 
intermediate care unit in a sealed package, only labeled with the name of the included patient. 
This allowed for blinding of the patient, nurses, urologist, pain service personnel, data assessors 
and statisticians. 
Randomization was done by computer-generated list, with blocks of 9 patients; allocation ratio 
was 1:1:1. Allocation sequence was left in concealed opaque and numbered envelopes. Patients 
were included strictly according to the lowest number.  
 
Primary and secondary outcomes:  
Primary endpoint was the time from start of the epidural analgesia to removal of the epidural 
catheter (i.e. duration of TEA). 
Secondary endpoints were epidural mixture rate (expressed in mL*h-1), total amount of epidural 
mixture used per 24 h, every step to reduce the epidural mixture (expressed in differences in 
epidural mixture rate from day to day, e.g. between postoperative day (POD) 4 vs POD 3, POD 5 
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vs POD 4 and POD5 vs POD 3), total number of patients per group still with TEA per 
postoperative day, and use of rescue analgesics (transformed in morphine equivalent). These 
parameters were recorded daily. We used the numeric rating score (NRS) for pain score 
assessment, whereby 0 = no pain and 10 = worst pain imaginable. The lowest, highest and 
average NRS were recorded at rest and during mobilization, which was defined as getting out of 
bed. NRS score was assessed during TEA checks at least 6 times per day. 
Additional secondary endpoints were the incidence of postoperative nausea and vomiting and 
return of bowel function (first defecation). Patients were actively questioned about nausea and 
episodes of vomiting were recorded. Documentation including time-points was recorded by 
dedicated study nurses. First flatus and defecation were recorded similarly. Episodes of 
constipation and ileus (i.e. delayed return of bowel function) were also recorded. Ileus was 
defined as postoperative nausea or vomiting associated with abdominal distension requiring 
cessation of oral intake and intravenous fluid support and/or nasogastric tube placement, or the 
intolerance of oral intake by POD 5 resulting in patient fasting.[34] Constipation was defined as 
inability to have a bowel movement by POD 5 with no signs of ileus or small bowel 
obstruction.[34] 
The end of the study was defined as removal of the epidural catheter and return of bowel 
function. 
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Standardized perioperative management: 
Preoperatively, no antegrade bowel preparation was administered, but two high enemas were 
given the evening before surgery. Patients had oral intake till midnight before surgery, and were 
encouraged to drink clear fluid till 2 hours before anesthesia induction.  
Standard monitoring included continuous electrocardiographic data, heart rate, nasopharyngeal 
core temperature, pulse oximetry, invasive mean arterial pressure with a radial artery catheter and 
central venous pressure with a venous catheter inserted in the right internal jugular vein. An 
epidural catheter was placed at the T9/T10 level. An 18 gauge epidural needle was inserted by a 
paramedian approach and the epidural space was identified with the loss-of-resistance technique. 
After a test dose of 1.5 mL lidocaine 2% with 0.005 mg*mL-1 epinephrine to rule out 
subarachnoid or intravascular placement, a 0.25% bupivacaine infusion at a rate of 6-8 mL*h-1 
was administrated. Anesthesia was induced with propofol (2 mg*kg-1), fentanyl (2 µg*kg-1) and 
rocuronium (0.6 mg*kg-1), and maintained with isoflurane at an age-corrected minimum alveolar 
concentration of 0.6. Normothermia was maintained with a convective air warming system (Bair 
Hugger™, 3M™-Switzerland, Rüschlikon, Switzerland) and using a Hotline® fluid warmer 
(Smith Medical International Ltd, Ashford, Kent, United Kingdom). 
Surgery was performed in a standardized fashion as previously described, with the patient in a 
30° head-down position [4; 6; 7]. A gastrostomy tube was placed intraoperatively and the 
orogastric tube was removed at the end of the procedure. The ureteral stents were exteriorized. 
The approach for supporting postoperative gastrointestinal function was standardized and AC
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according to our internal ERAS program guidelines for cystectomy patients. [26] The use of 
chewing gum was encouraged and clear drinks were allowed the same evening after surgery. 
Gastrostomy tube was initially left on drainage, and closure of the gastrostomy tube was initiated 
if no nausea and vomiting was present for > 24 h. Bedside mobilization was encouraged as soon 
as possible, ideally the same evening after surgery, if not possible not later than the next morning. 
Gastrointestinal ulcer prophylaxis was done with esomeprazole (for > 48 h). Oral fluids included 
energy drinks (Resource Senior Active®, Nestlé Health, Switzerland or Ensure®, Abbott 
Nutrition, Switzerland) on POD 1. The protocol included administration of subcutaneous 
neostigmine 0.25 to 0.5 mg as prokinetic up to 3 times per day, and peroral laxatives starting on 
POD 2. Small snacks or mashes were encouraged and introduced on POD 2 but not later than on 
POD 3. On POD 3, longer mobilization including walking distance and spending time on a chair 
were encouraged. The gastrostomy tube was removed once the patient had normal stool passage. 
Intervention: 
The epidural analgesia was activated during closure of the abdominal wall with bupivacaine 1.25 
mg*mL-1 (Bupivacaine 0.125% Bioren™, Sintetica-Bioren, Couvet, Switzerland) using a CADD 
Legacy ambulatory infusion pump (model 6300, Deltec Inc., St Paul, MN). The initial infusion 
rate was 8 mL*h-1, with a maximum infusion rate of 15 mL*h-1, and with additional bolus doses 
of 5 mL (lockout time: 1 h) from the end of surgery till 8 am on POD 3. The infusion rate could 
be adapted if necessary to maintain a NRS < 3 at rest and < 5 during mobilization based on 4 
hourly assessments. 
Starting from 8 a.m. on POD 3, patients received blinded batches with oxycodone, 
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oxycodone/naloxone or placebo every 12 h. The oxycodone/naloxone arm received 10 mg / 5 mg 
for the first day, followed by 20 mg / 10 mg for the remaining 4 days. The oxycodone arm 
received 10 mg for the first day, followed by 20 mg for the remaining 4 days. On POD 4, 
attempts to reduce the epidural infusion rate were made in steps of 2 mL to maintain a NRS < 3 at 
rest and < 5 during mobilization for 6 h. The epidural catheter was removed when a rate of 2 
mL*h-1 achieved a NRS < 3 and < 5 at rest and during mobilization for 6 h. If the epidural 
catheter could not be removed because of regular prophylactic subcutaneous administration of 
heparin which was always administered at 8 p.m., the epidural infusion was stopped and duration 
of TEA registered (as removal of the epidural catheter). The catheter was then removed 12 h after 
the heparin injection according to our guidelines. First rescue medication for breakthrough pain 
episodes was additional epidural boluses of 5 mL, limited to one bolus per hour. In case of 
persistent pain, orally administered 5 mg of immediate-release oxycodone every 6 hours was 
allowed as a second rescue medication in the three arms. In all groups, metamizol 1 g 
intravenously were given in the intermediate care unit and repeated every 6 h until return of 
bowel function and then orally administered as a supplement for postoperative analgesia. 
Statistics: 
Considering the primary objective to compare oxycodone (with and without naloxone) with 
placebo for the duration of TEA, defining a mean difference of duration of TEA of 1 day as 
clinically relevant, and expecting a standard deviation of 1 day (based on our internal data), 23 
patients per group is the minimum sample size.[32] This was based on the null hypothesis for the 
proposed study that the duration of TEA was equal across the populations. The criterion for 
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significance (α) was set at 0.0167 due to the correction for 3 multiple tests (oxycodone/naloxone 
vs. oxycodone, oxycodone vs. placebo, and oxycodone/naloxone vs. placebo, Bonferroni 
corrected). The test was 2-tailed. With a sample size of 23 patients per group, the study would 
have a power of 81.2% to yield a statistically significant result. The computation assumes a 
common within-group standard deviation of 1. Considering a drop out frequency of a bit more 
than 20%, 30 patients per group needed to be recruited and a thus total of 90 patients were 
included. The calculations were made with SamplePower statistical software (v 3.01, IBM, 
Armonk, New York) and were based on a t-test for independent groups with common variance. 
Data were analyzed on a modified intention to treat basis (two patients were excluded after 
randomization). Data were expressed with means and standard deviations (±SD) or medians 
accompanied with nonparametric 95% confidence intervals (CI) or ranges for continuous 
variables as appropriate and as frequencies for categorical ones after checking for normality of 
distribution (Q-Q plots). Categorical data were compared with the chi square test and continuous 
data by analysis of variance (ANOVA) or Kruskal Wallis (for primary outcome) as appropriate. 
If ANOVA was significant, Bonferroni correction were applied to account for multiple 
comparisons. All analyses were performed using STATA statistical software (v 14.0, StataCorp 
LP, College Station, Texas). 
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Results: 
Of 110 consecutive patients scheduled for open cystectomy and urinary diversion 90 fulfilled the 
eligibility criteria and were randomized. Of the 90 patients enrolled, 2 patients in the 
oxycodone/naloxone were excluded because of non-functional TEA after surgery and were 
excluded from the analysis (Figure 1). Preoperative baseline characteristics were similar among 
the three groups (Table 1).  
Primary endpoint: 
The duration of TEA did not differ significantly among the three groups (oxycodone/naloxone: 
median 6.7 [range 3.1 to10.3] days, oxycodone: 7.0 [3.0 to9.1] days or placebo: 6.4 [3.1 to 8.4]; 
P=0.880,(Figure 2). 
 
 
Secondary endpoints: 
The median epidurally administered mixture rate, median total amount of drug administered 
epidurally, number of boluses administered and the median amount of systemic administered 
rescue analgesics (morphine equivalent) did not differ significantly among the 3 groups at any 
time point. A significant reduction of the median epidural mixture rate was achieved in the 
oxycodone/naloxone (difference 1.41 mL/h [95% CI 0.01-2.73]; P=0.036] and in the oxycodone 
groups (2.17 mL/h [95% CI 0.77-3.57]; P=0.003] on POD 4 compared to POD 3 (Table 2). The 
number of patients who were still under TEA after POD 4 was similar among the groups (on 
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POD 5: oxycodone/naloxone: 26/28 (93%), oxycodone: 29/30 (97%), placebo: 29/30 (97%); 
P=0.727; on POD 6: oxycodone/naloxone: 20/28 (71%), oxycodone: 23/30 (77%), placebo: 
26/30 (87%); P=0.356; on POD 7: oxycodone/naloxone: 14/28 (50%), oxycodone: 15/30 (50%), 
placebo: 15/30 (50%); P=1.000; on POD 8: oxycodone/naloxone: 6/28 (21%), oxycodone: 4/30 
(13%), placebo: 6/30 (20%); P=0.691). 
The median average pain scores at rest and during mobilization did not differ significantly 
between the 3 groups at any time point (Figure 3). 
The time in hours to first flatus did not differ significantly among the groups 
(oxycodone/naloxone mean 48.40 ±24.48 SD, oxycodone: 42.41 ±24.16, placebo: 43.19 hours 
±25.76; P=0.622). The time in hours to first defecation differed among the groups 
(oxycodone/naloxone mean 85.91 ±27.68 SD, oxycodone 97.69 ±35.70, placebo: 75.21 hours 
±35.44; P =0.048). Pairwise comparison showed a significant difference in means between the 
placebo group and the oxycodone group (22.48 hours ±8.95; P=0.037). The difference between 
the placebo group and the oxycodone/naloxone group and between the oxycodone group and the 
oxycodone/naloxone group were not statistically significant (10.70 hours ±9.15; P=0.475 and 
11.78 ±9.46; P=0.430, respectively). Delayed return of bowel function significantly differed 
among the groups (oxycodone/naloxone: 5/28 patients (17%), oxycodone: 14/30 patients (47%), 
placebo: 7/30 patients (23%); P=0.027). In the oxycodone group, we found 8/30 patients with 
ileus (27%) compared to 2/28 (7%) in the oxycodone/naloxone group and to 2/30 patients in the 
placebo group (7%) (P=0.031).  
Episodes of postoperative nausea and vomiting within 48 hours postoperatively were similar 
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among the groups (POD 1: oxycodone/naloxone: 3/25 (12%), oxycodone 6/24 (17%), placebo 
4/26 (15%); P=0.507, POD 2: oxycodone/naloxone: 3/25 (12%), oxycodone 6/24 (17%), placebo 
3/27 (11%); P=0.456). 
This study did not demonstrate any significant difference among the groups in regard to other 
opioid side effects or adverse events such as nausea, vomiting after initiation of administration of 
the allocated drugs (POD 3: oxycodone/naloxone: 3/25 (12%), oxycodone 4/26 (15%), placebo 
4/26 (15%); P=0.507; POD 4: oxycodone/naloxone: 3/25 (12%), oxycodone 3/27 (11%), placebo 
1/29 (3%); P=0.804; POD 5: oxycodone/naloxone: 4/16 (25%), oxycodone 3/20 (15%), placebo 
3/23 (13%); P=0.840; POD 6: oxycodone/naloxone: 3/17 (18%), oxycodone 6/17 (35%), placebo 
4/22 (18%); P=0.553; POD 7: oxycodone/naloxone: 2/12 (17%), oxycodone 2/13 (15%), placebo 
1/14 (7%); P=0.777; POD 8: oxycodone/naloxone: 3/3 (50%), oxycodone 2/2 (50%), placebo 4/2 
(67%); P=0.801. There were no cases of respiratory depression or strong sedation. There were no 
cases of TEA catheter associated infections. 
 
Discussion: 
The early postoperative oral administration of prolonged-release oxycodone with or without 
naloxone starting on POD 3 did not reduce the duration of TEA compared to placebo. Pain scores 
were not affected by the study drugs and all groups had optimal analgesia at rest and during 
mobilization (mean NRS lower than 3 in all groups at any time points). Most of the secondary 
endpoints were not different among groups, indirectly confirming that the addition of oxycodone, AC
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with or without naloxone, did not improve pain management. We did however, find a prolonged 
time to first defecation and a higher incidence of postoperative ileus in patients who received 
oxycodone alone. As this study failed to demonstrate the superiority of early administration of 
oxycodone or oxycodone/naloxone alone to reduce the duration of TEA, these results question 
the practice of early postoperative oral administration of these medications in patients managed 
with TEA after cystectomy. 
The rationale behind the choice of oxycodone was that other at equivalent analgesic dosage µ-
opioid agonists, such as fentanyl and morphine, may not be optimal for treating visceral pain. 
Open cystectomy with urinary diversion is a major abdominopelvic surgery involving extensive 
mobilization/resection of the peritoneum and a small bowel anastomosis and as such is 
accompanied by visceral pain. The main mechanism of action for oxycodone is stimulation of the 
peripheral and central opioid µ and k receptors. It has been suggested that k receptors constitute 
an essential part in the analgesic mechanism of action of oxycodone. Opioid k receptors may be 
important for treatment of visceral pain, and hence oxycodone could have a high therapeutic 
efficacy in this setting.[38; 41] 
The rationale behind the oral prolonged-release oxycodone/naloxone formulation is to prevent 
opioid-induced bowel dysfunction through the local antagonist effect of naloxone in the gut wall, 
while analgesia is maintained due to the negligible systemic absorption of oral naloxone. Indeed, 
the bioavailability of oral naloxone is less than 3% as it undergoes extensive first-pass hepatic 
metabolism. Naloxone binds to µ-opioid receptors on the neurons of the myenteric plexus of the 
gastrointestinal tract with a higher affinity than oxycodone.[8] Time to first defecation was 
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slightly longer with prolonged-release oxycodone alone compared to placebo, but not compared 
to oxycodone/naloxone. As the power calculation of this study was not based on this parameter, 
we cannot exclude that the non-significance between the placebo group and the 
oxycodone/naloxone group and between the oxycodone group and the oxycodone/naloxone 
group might be the result of lack of power. However, these results confirm precedent 
observations on healthy volunteers showing that prolonged-release oxycodone significantly 
extended colon arrival time compared to placebo and that the addition of prolonged-release 
naloxone resulted in similar colon arrival time as placebo.[35] The gastrointestinal effects of 
oxycodone are complex as both excitatory and inhibitory neural inputs to the gastrointestinal 
muscle layer can be interrupted. The activation of the µ-opioid receptors on myenteric and 
submucosal neurons in the lamina propria of the stomach, small and large intestines walls play a 
major role.[22] On one hand, inhibition of excitatory neural inputs reduce distension-induced 
peristaltic contraction. On the other hand, the blockade of inhibitory neural inputs increases 
gastrointestinal muscle activity and resting muscle tone is elevated. This results in 
delayed/inhibited gastric emptying, increased pyloric muscle tone, delayed transit through the 
intestines and elevated resting anal sphincter tonus.[8; 22; 28; 37] While the benefit of 
prolonged-release oral oxycodone/naloxone on constipation has been well established in chronic 
pain treatment[11; 17; 40] and cancer patients[2], the benefit is less clear in the perioperative 
setting. In our opinion, this is the first study in which prolonged-release oxycodone with or 
without naloxone were administered early after major abdominopelvine surgery with small bowel 
surgery. The literature on postoperative administration of prolonged- release oxycodone with or 
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without naloxone is scarce and mostly focused on orthopedic joint surgery and minimal-invasive 
gynecological hysterectomy. [12; 23] If prolonged-release oxycodone with naloxone offers a 
similar analgesia compared to oxycodone alone with better gastrointestinal function, in the 
chronic pain patients, these observations are inconclusive in the postoperative setting. An 
explanation could also be the short period of treatment. Comelon et al. found no benefit of 
oxycodone/naloxone compared to oxycodone alone in patients undergoing laparoscopic 
hysterectomy. However, they used oxycodone as a first line analgesic treatment, and no regional 
technique was used with the exception of bupivacaine injection at the incision sites.[12] 
An explanation why prolonged-release oxycodone failed to reduce the duration of TEA could be 
the specific pharmacokinetic conditions related to the early postoperative setting of a small bowel 
resection and anastomosis.[31] Indeed, the bioavailability of orally administered oxycodone is 
high in healthy volunteers, however if this can be projected in these cystectomy patients is 
questionable.[36] Delayed gastrointestinal recovery is frequent after cystectomy and urinary 
diversion and is considered an important driver for LOS after cystectomy.[10] The postoperative 
ileus related increased length of hospital stay may in turn contribute to nosocomial infections and 
increased readmission rate. In this study, the early oral administration of prolonged-release 
oxycodone alone increased the time to first defecation compared to placebo, without affecting 
pain scores or duration of TEA. Therefore, this treatment option cannot be recommended after 
cystectomy due to the increased risk of postoperative ileus. This is an important consideration as 
this is in line with the ERAS recommendation to avoid the use of opioids and to implement a 
multimodal opioid free postoperative analgesia.[15]  
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This study was powered to determine a difference in duration of TEA. This choice as primary 
endpoint may be considered as a limitation, given the variability of this measure depending on 
the patient population. Most randomized clinical trials on analgesic techniques were powered on 
pain intensity reduction (NRS). However, in this study, the focus was to determine if, after 3 
days, systemic administration of prolonged release analgesics is a viable alternative to TEA 
without impairing the beneficial side effect of TEA. A potential limitation could be postoperative 
gastroparesis as oxycodone could be liberated in the stomach but not absorbed, thus after return 
of gastric function a supranormal systemic concentration of the liberated drugs could occur due to 
the absorption in the small bowel. However, here all patients had a gastrostomy and according to 
our internal protocol, in case of dysmotility or upper abdominal discomfort, this could be left 
open, allowing for liberation of gastric content. In addition, this trial was a three-way 
comparison. This led to multiple significance tests and possibly to misleading P-values. 
An additional limitation of this study is the relative long duration of TEA compared to other 
centers, potentially limiting the generalization of our findings. Indeed, most ERAS protocols 
including rectal/pelvic surgery and the new guidelines of the ERAS society for perioperative care 
after radical cystectomy do recommend to leave the TEA in place for 48 to 72 hours 
postoperatively.[9; 29] However, these recommendations are based on low level evidence in 
cystectomy patients, and the optimal duration of epidural analgesia in terms of patient outcomes 
and satisfaction is still unclear.[27] Due to the excellent analgesic properties, reduction of 
surgical stress, minimization of catabolic and inflammatory response, facilitation of recovery of 
bowel function and enhancement of functional recovery, some institutions prefer to keep the 
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epidural catheter longer.[15; 33] Noticeably, Lee et al. found a gastrointestinal recovery time 
(defined as first toleration of food, and first bowel movement) of 5.5 days using alvimopan to 
accelerate gastrointestinal recovery,[24] and in a previous randomized clinical trial we found that 
normal bowel function (normal feces) returned at around 6 days after surgery.[25] Because of the 
variable practice, our results remain applicable to clinical settings using a similar protocol.  
Conclusion:  
In conclusion, neither early oral administration of prolonged-release oxycodone combined with 
naloxone, nor oxycodone alone, could reduce the duration of TEA. As the time to first defecation 
was increased in patients treated with oxycodone alone and the medication conferred no 
additional benefit in term of analgesia, early postoperative administration of oxycodone cannot be 
recommended in patients undergoing cystectomy and urinary diversion. Although the addition of 
naloxone counteracted the negative impact of oxycodone alone on bowel function, the overall 
effect was not different from placebo. Therefore, also the combination cannot be recommended. 
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Figure legends: 
Figure 1: CONSORT flow diagram: 
Figure 2: Duration of TEA: Data presented as box plots with horizontal bars designating the 
median values, the vertical bars the 10th and 90th percentiles, and the open circles the extreme 
values. No significant differences between the 3 groups. 
Figure 3: Pain scores with NRS scale mean value per day at rest (A) and during mobilization (B) 
per day according to the groups. No significant differences between the 3 groups at any time 
point. Data presented as box plots with horizontal bars designating the median values, the vertical 
bars the 10th and 90th percentiles, and the open circles the extreme values. 
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Table 1: Baseline characteristics 
 
   Placebo 
Oxycodone/ 
naloxone Oxycodone Overall 
Gender female n/total (%) 11/30 (37%) 10/30 (33%) 10/30 (33%) 31/90 (34%) 
 
male n/total (%) 19/30 (63%) 20/30 (67%) 20/30 (67%) 59/90 (66%) 
ASA 2 n/total (%) 10/30 (33%) 18/30 (60%) 12/30 (40%) 40/90 (44%) 
 
3 n/total (%) 18/30 (60%) 8/30 (27%) 18/30 (60%) 44/90 (49%) 
 
4 n/total (%) 2/30 (7%) 4/30 (13%) 0/30 (0%) 6/90 (7%) 
 
 mean (SD) 2.73 (±0.58) 2.53 (±0.73) 2.6 (±0.5) 2.62 (±0.61) 
Age [Years]  mean (SD) 67 (±15.25) 
66.03 
(±12.19) 
68.47 
(±11.47) 
67.17 
(±12.96) 
Weight [kg]  mean (SD) 74.31 (±18.9) 77.6 (±15.36) 
79.25 
(±15.15) 77.05 (±16.5) 
Height [cm]  mean (SD) 168.63 (±9) 
168.93 
(±7.88) 
171.07 
(±9.26) 169.55 (±8.7) 
BMI  mean (SD) 25.84 (±4.76) 27.15 (±5.12) 27.08 (±4.68) 26.69 (±4.84) 
Smoking [Pack Years]  mean (SD) 
18.67 
(±26.49) 15.4 (±22.54) 
14.43 
(±25.17) 
16.17 
(±24.56) 
Antihypertensive  n/total (%) 19/30 (63%) 16/30 (53%) 14/30 (47%) 49/90 (54%) 
Beta-blocker  n/total (%) 5/30 (17%) 5/30 (17%) 7/30 (23%) 17/90 (19%) 
Statin  n/total (%) 7/30 (23%) 8/30 (27%) 8/30 (27%) 23/90 (26%) 
Aspirin  n/total (%) 9/30 (30%) 8/30 (27%) 3/30 (10%) 20/90 (22%) 
Oral anti-diabetics  n/total (%) 6/30 (20%) 5/30 (17%) 6/30 (20%) 17/90 (19%) 
Performed surgical intervention     
Orthotopic ileal bladder 
substitute  n/total (%) 9/30 (30%) 9/30 (30%) 10/30 (33%) 28/90 (31%) 
Ileal conduit  n/total (%) 19/30 (63%) 12/30 (40%) 19/30 (63%) 50/90 (56%) 
Continent catheterizable 
ileal reservoir  n/total (%) 1/30 (3%) 7/30 (23%) 1/30 (3%) 9/90 (10%) 
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Other  n/total (%) 1/30 (3%) 2/30 (7%) 0/30 (0%) 3/90 (3%) 
Intraoperative fentanyl 
(µg)  mean (SD) 
394.2 
(±172.4) 
341.7 
(±230.1) 
415 (±191.8) 383.6 
(±199.7) 
Epidural rate (mL/h)  mean (SD) 6.7 (±1.73) 6.72 (±1.75) 7.47 (±0.9) 6.97 (±1.53) 
Abbreviations: ASA = American Society of Anesthesiologists classification; BMI = body mass 
index; n = number of patients; SD = standard deviation 
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Table 2: Difference (diff) in bolus administration, total epidural mixture administered per day, 
epidural mixture rate and rescue medication between postoperative day (POD) 3 (after having 
started the allocated drug) versus POD 4 and POD 5. Data presented as mean differences, 
standard deviation (±SD) and P-value. 
 POD 3 vs 4 POD 3 vs 5 POD 4 vs 5 
 diff (±SD) p diff (±SD) p diff (±SD) p 
Total epidural mixture rate (mL/d)    
oxycodone/naloxone 
-22.9 (±90.94) 
0.19 
-74.45 (±98.08) 
<0.01 
-47.59 (±97.44) 
0.01 
oxycodone 
-31.41 (±86.46) 
0.06 
-81.1 (±90.29) 
<0.01 
-50.97 (±100.31) 
0.01 
placebo 
-17.17 (±95.02) 
0.34 
-53.24 (±102.84) 
0.01 
-33.14 (±105.67)   
0.1 
Epidural mixture rate (mL/h)    
oxycodone/naloxone -1.41 (±3.46) 0.04 -3.17 (±3.68) <0.01 -1.69 (±3.76) 0.02 
oxycodone 
-2.17 (±3.68) 
<0.01 -3.55 (±3.58) <0.01 -1.31 (±3.85) 0.08 
placebo -1.16 (±4.09) 0.14 -2.79 (±3.94) <0.01 -1.53 (±3.98) 0.05 
Rescue analgesia (morphine equivalent)   
oxycodone/naloxone 0.61 (±1.39) 0.03 0.44 (±1.31) 0.08 -0.12 (±2.03) 0.76 
oxycodone -0.2 (±1.07) 0.32 -0.26 (±0.91) 0.14 -0.06 (±0.69) 0.66 
placebo 0.43 (±2.91) 0.43 0.63 (±3.43) 0.33 0.26 (±4.01) 0.73 
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